The Peptide NewsroomPeptide research, industry and supply-chain headlines

Leslie Mann Says Judd Apatow Has Gained 15 Pounds in Four Years on Ozempic

Topic card: semaglutide glp-1

Leslie Mann told the audience on Jimmy Kimmel's show that her husband, filmmaker Judd Apatow, is taking Ozempic and has gained weight on it. "He's on Ozempic, he likes to talk about it, and he has gained, like, 15 pounds in four years," Mann, 54, said on the August 27 episode, adding that he is on the highest dose.

Ozempic is a brand name for semaglutide, one of the GLP-1 drugs built on peptide hormones that signal fullness to the brain and gut. Us Weekly notes the medication is commonly prescribed to adults with weight-related conditions including diabetes, and that doctors have warned against its use for casual weight loss.

What Mann described

By her account, the weight gain is not a failure of the drug so much as a project. He "likes to outrun the feeling that you get that Ozempic gives you to stop eating," she said, and "likes to, like, override it or outrun it."

She framed it as a point of pride for him: "He's very proud of the fact that the pharmaceutical companies don't have control over him." Her own verdict on the whole arrangement was two words: "It's so weird."

Apatow's own version

This is not new material for him. During a 2024 stand-up show in New York City, the 58-year-old director said he had been on the drug for six months and gained four pounds, describing the nausea as something he treated "as a challenge to eat through."

He put a number on the experiment in that same set, saying it cost him $40,000. He also described eating ice cream and dosing at the same time "just to see who wins the battle," and called the result a draw.

Anecdote, not data

What is on the record here is one person describing his own behavior on a talk show and in a comedy routine, relayed by his wife. There is no trial, no clinician quoted, and no published data anywhere in this story.

That matters because celebrity GLP-1 talk is doing a lot of unearned work in this category right now, in both directions. A funny story about deliberately eating through nausea tells you nothing about how the drug performs in people who are not trying to defeat it.

The open question

The interesting thread Mann pulled on is behavioral, not pharmacological: what happens when appetite suppression meets someone determined to override it. Nobody in this story is studying that, and the answer here is a punchline rather than a finding.

Source: Us Weekly. Read the original.

Filed under: glp-1

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

GLP-1 Drugs Linked to Rare Sudden Vision Loss, But Absolute Risk Stays Low

A Rutgers-led study published in Annals of Internal Medicine links GLP-1 drugs including Ozempic and Wegovy to a modest increase in ischemic optic neuropathy, a rare condition that can cause sudden vision loss. The lead author put the increase at roughly three to four additional cases per 10,000 patients over 18 months, and says the data does not establish causation.

Telangana Regulator Warns Online Peptide Buyers Risk Contamination, Serious Reactions and Death

Telangana's drug regulator TG SAFE has warned against buying or self-administering unapproved weight-loss drugs and experimental peptides sold on Telegram and other online platforms, naming BPC-157, GHK-Cu, retatrutide and tesamorelin. The advisory says such products may be contaminated, mislabelled or untested for sterility, and directs doctors not to prescribe them.

Gray Market Peptide Users Report Months of Side Effects, and the Research Is Thin

KFF Health News, written up by Futurism, reports on users of research-grade BPC-157 who describe fatigue, spasms and migraines lasting months after a few days of use. A former FDA official quoted in the piece says robust human studies on these compounds remain rare.